Loading
Lung Cancer Treatments and Mutations / Ferroptosis and Cancer Prognosis · Journal article
BMC Bioinformatics · September 8, 2026
Raises a question worth testing. It does not answer one.
This computational study proposes that gain-of-function mutant p53 physically sequesters FOXP3, preventing its occupancy at the CD274 (PD-L1) promoter and driving immune evasion in lung adenocarcinoma. A disrupted FOXP3–PD-L1 axis associates with significantly inferior overall survival (HR 1.48, p=6×10⁻⁴, N=670), and AlphaFold 3 predicts a stable mutp53–FOXP3 heterodimer with molecular dynamics supporting favourable binding energetics; however, the proposed mechanism lacks experimental confirmation through co-immunoprecipitation, ChIP-seq, or promoter-reporter assays.
Computational modelling study integrating retrospective cohort survival analysis, transcription factor occupancy prediction, chromatin accessibility profiling, structural protein prediction, and molecular dynamics simulation. Lung adenocarcinoma (LUAD) patients across three independent cohorts (TCGA PanCancer Atlas n=510, OncoSG n=181, CPTAC n=110). Pan-cancer transcriptomics included 8 TCGA cohorts (N=4,205) to assess lineage specificity. ATAC-seq profiling compared LUAD and head-and-neck squamous cell carcinoma (HNSC).. Intervention: Presence of gain-of-function mutant TP53 (mutp53); analysis of FOXP3–CD274 regulatory axis. Compared with: Wild-type or absent TP53 mutation; intact FOXP3–CD274 regulatory axis. Multi-centre international cohorts: TCGA PanCancer Atlas, OncoSG, CPTAC; geography of OncoSG and CPTAC not explicitly stated in abstract.
Disrupted FOXP3-PD-L1 axis significantly predicted inferior OS: log-rank p=6×10⁻⁴, HR=1.48, 95% CI 1.12–1.95 across N=670 LUAD patients FIMO identified 8 candidate FOXP3 consensus motif positions (GTAAACA; p=7.93×10⁻⁵) on CD274 promoter pending ChIP-seq confirmation AlphaFold 3 predicted stable mutp53-FOXP3 heterodimer with pLDDT>70 at interface
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
If experimentally validated, disruption of the mutp53–FOXP3 axis could explain PD-1/PD-L1 checkpoint therapy resistance in approximately half of LUAD patients and identify a rational therapeutic target. Currently, this remains a candidate mechanism requiring functional confirmation before clinical application.
Multi-scale computational prediction of a candidate mutp53-FOXP3 interaction mechanism, supported by associational survival data and in silico modelling but lacking experimental validation of physical sequestration or functional causality.
As stated by the source record.
Quoted from the source exactly as published.
If experimentally validated, disruption of the mutp53–FOXP3 axis could explain PD-1/PD-L1 checkpoint therapy resistance in approximately half of LUAD patients and identify a rational therapeutic target. Currently, this remains a candidate mechanism requiring functional confirmation before clinical application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Immune checkpoint therapy (ICT) targeting PD-1/PD-L1 fails in nearly half of lung adenocarcinoma (LUAD) patients. Tumor-cell-intrinsic FOXP3 directly regulates CD274 (PD-L1) transcription. I hypothesized that gain-of-function (GOF) mutant p53 (mutp53) physically sequesters FOXP3, preventing CD274 promoter occupancy and enabling unchecked PD-L1 expression in a lineage-specific manner. Six-layer multi-scale computational analysis: (1) clinical survival meta-analysis across three independent LUAD cohorts (TCGA PanCancer Atlas n = 510, OncoSG n = 181, CPTAC n = 110; N = 670); (2) FIMO transcription factor occupancy analysis (JASPAR 2024 MA0850.1) on the CD274 promoter; (3) ATAC-seq chromatin accessibility profiling across LUAD/HNSC lineages; (4) AlphaFold 3 mutp53-FOXP3 complex prediction with PAE analysis; (5) AMBER ff19SB/TIP3P molecular dynamics (2 ns NPT, 310 K, 0.15 M NaCl, A100 GPU); (6) pan-cancer transcriptomic analysis (8 TCGA cohorts, N = 4,205; DESeq2/Spearman) from preprint [36]. Disrupted FOXP3-PD-L1 axis significantly predicted inferior OS (log-rank p = 6 × 10 −4, N = 670; HR = 1.48, 95% CI: 1.12–1.95). FIMO identified 8 candidate FOXP3 consensus motif positions (GTAAACA; p = 7.93 × 10 −5 ) on the CD274 promoter pending ChIP-seq confirmation. ATAC-seq revealed lineage-specific chromatin restriction at CD274 in LUAD but not HNSC. AlphaFold 3 predicted a stable mutp53-FOXP3 heterodimer (pLDDT > 70 at interface). AMBER MD demonstrated progressive complex compaction (Rg: 46.7→43.9 Å), significant inter-chain correlated motion, rigid interface geometry (RMSF 1–2 Å, residues 150–300), and estimated interaction energy of − 55.33 kcal/mol. From preprint [36]: mutp53 upregulates CD274 (log 2 FC = 0.53, padj < 0.0001) without altering FOXP3 (log 2 FC = 0.014, padj = 0.889) in 517 TCGA-LUAD samples; 67% adenocarcinoma versus 0% non-adenocarcinoma FOXP3-checkpoint uncoupling ( N = 4,205). Multi-scale computational evidence supports a candidate mutp53-FOXP3 sequestration interaction potentially abrogating FOXP3 occupancy at 8 candidate CD274 promoter positions, associated with PD-L1 overexpression and significantly inferior survival across 670 LUAD patients. Experimental validation via co-IP, ChIP-seq, and promoter reporter assays is required to confirm physical sequestration. This lineage-specific mechanism identifies the mutp53-FOXP3 interface as a high-priority candidate therapeutic target.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.